Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 11, 2004, Pages 1924-1933

  Dhainaut, J F ^a   Yan, S B ^b   Joyce, D E ^b   Pettila V ^c   Basson, B ^b   Brandt, J T ^b   Sundin, D P ^b   Levi, Marcel ^d  

^a Paris V University ^*  (France)

^b ELI LILLY AND COMPANY   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Disseminated intravascular coagulation; Drotrecogin alfa (activated); Severe sepsis

Indexed keywords

DROTRECOGIN; PLACEBO;

ADULT; AGED; ALGORITHM; ARTICLE; BLEEDING; BLEEDING TENDENCY; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCORING SYSTEM; SEPSIS;

ADULT; AGED; ALGORITHMS; DATA COLLECTION; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN C; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SEPSIS; SEVERITY OF ILLNESS INDEX; THROMBOPHILIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 1842547895     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00955.x     Document Type: Article

References (18)

1. Levi M, Ten Cate H. Disseminated intravascular coagulation. New Engl J Med 1999; 341: 586-92.
2. Hardaway RM, Williams CH, Vasquez Y. Disseminated intravascular coagulation in sepsis. Sem Thromb Hemost 2001; 27 577-83.
3. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-23.
4. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996; 75: 224-8.
5. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86 1327-30.
6. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. New Engl J Med 2001; 344: 699-709.
7. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101 1644-55.
8. Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G, Kinasewitz GT for the PROWESS Sepsis Study Group. Drotrecigin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003; 90: 642-53.
9. Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE Jr, Russell JA, Mayers I, Rosenfeld BA, Morris PE, Yan SB, Helterbrand JD. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001; 29: 2051-9.
10. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T. The revised CONSORT statement for reporting randomized trials: explanation and elaboration [see comment]. Ann Intern Med 2001; 134: 663-94.
11. Agresti A. Categorical Data Analysis. New York: John Wiley and Sons, Inc. 1990.
12. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-25.
13. Welty-Wolf KE, Carraway MS, Miller DL, Ortel TL, Ezban M, Ghio AJ, Idell S, Piantadosi CA. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 2001; 164: 1988-96.
14. Levi M, Vasquez Y, Ten Cate H. Blood. Principles and Practice of Hematology. Philadelphia, PA: Lippincott, 2002.
15. Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR for the PROWESS investigators. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31: 12-9.
16. Kerlin BA, Yan SB, Isermann BH, Brandt JT, Sood R, Basson BR, Joyce DE, Weiler H, Dhainaut JF. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003; 102: 3085-92.
17. Akca S, Haji-Michael P, de Mendonca A, Suter P, Levi M, Vincent JL. Time course of platelet counts in critically ill patients. Crit Care Med 2002; 30: 753-6.
18. Wada H, Mori Y, Okabayashi K, Gabazza EC, Kushiya F, Watanabe M, Nishikawa M, Shiku H, Nobori T. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients. Am J Hematol 2003; 72: 1-7.